

See “Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study” on pages 350-360.

Supplementary Table 1. Patients Who Discontinued Adalimumab and Related Reasons

Related reason	Value (n = 62)
Lack of efficacy	34 (54.8)
Adverse event	11 (17.7)
Follow-up loss	9 (14.5)
Subject's decision	6 (9.7)
Pregnancy	1 (1.6)
Others	1 (1.6)

Values are presented as number (%).